Cellular therapies and tissue engineering company Lattice Biologics Ltd (TSX-V:LBL) (OTCBB:LBLTF) stated on Monday that it recorded a net loss of USD0.3m (USD0.00 per share) for the third quarter of 2020.
This is flat when compared with a net loss of USD0.3m (USD0.00 per share) for the same period in the prior year.
Gross profit of USD0.1m was recorded for the three months ended 30 June 2020, down over USD0.2m in the comparable previous year.
Sales of USD0.5m were announced for the three months ended 30 June 2020, a dip from sales of USD0.4m in the third quarter of 2019.
Lattice Biologics' CEO Guy Cook said the company has continued to maintain its relationship with critical customers during the COVID-19 pandemic, with sales increasing 13% year over year. It expects revenues to continue to grow to the USD3.5 to 4.0m range for 2021.
CVS Health declares unchanged quarterly dividend
ALK partners with GenSci to expand allergy immunotherapy market in China
Curatis secures Swiss distribution deal with Phoenix Labs
Innocan Pharma reports 'positive swing' in operating profitability for first half of 2025
Wolters Kluwer boosts medical research efficiency with Ovid AI summarisation
European Commission approves Gilead's twice-yearly HIV prevention injection Yeytuo
Essa Pharma clarifies Nasdaq due bill trading period for cash distribution
Advanz Pharma and Alvotech secure European approval for aflibercept biosimilar Mynzepli
Heron Therapeutics announces tax benefits preservation plan adoption
Essa Pharma sets ex-dividend date and due bill trading for USD80m capital return
BioDlink's bevacizumab injection secures Colombia and Pakistan marketing authorisation
GSK to receive USD370m and future royalties in CureVac/BioNTech settlement
Everest Medicines expands I-MAB investment
Perrigo Announces Quarterly Dividend
Ridgetech reports net income of USD10.20m in fiscal year 2025